{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 39,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses a process flow diagram to illustrate the trial structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/22",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.6,
        "x": 0.35,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Phase 1b to Phase 2 flow showing Part A, B, and C treatment arms.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42a275b6-61cb-4b4c-8232-9f1f7bada33c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "IMDC = International Metastatic RCC Database Consortium (Risk), TKI = tyrosine kinase inhibitor. Cabozantinib dosing as indicated on the package insert",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0e8035f-28ad-42dd-8178-0cbd2ca31384",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Population: 26 patients (P1b) and 55 patients (P2); Histologically confirmed metastatic ccRCC; Patients previously treated with cabozantinib are excluded. P1B Population: 100% prior immunotherapies; ~60% VEGF TKIs; >70% intermediate/poor IMDC; ~40% >1 prior line.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e09903d-3374-4919-a598-3176b71e80bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC (NCT04300140)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ca93588-15c8-4f3f-86b7-df9650d90721",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "1978af7b-d1d0-4ef8-8134-34dd2c6ddba1",
      "evidence": "diagram/process: Phase 1b to Phase 2 flow showing Part A, B, and C treatment arms.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "f3493f45-8f42-47b8-873c-3f15a926e9ac",
      "evidence": "Flowchart showing trial progression from Phase 1b to Phase 2 arms",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}